LBA2 Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase III KEYNOTE-905 study
Christof Vulsteke, H. Kaimakliotis, Pongwut Danchaivijitr, Maksim Sabadash, Alejo Rodríguez‐Vida, Zuo‐Feng Zhang, V. Atduev, Y.E. Goger, Steffen Rausch, Su Hwan Kang, Y. Loriot, J. Bedke, M.D. Galsky, Peter H. O’Donnell, Martin Mihm, Changting Meng, Dong-xin Huang, C. Ramamurthy, Blanca Homet Moreno, A. Ullén
Topics & Concepts
MedicinePembrolizumabInternal medicineOncologyBladder cancerPerioperativePhases of clinical researchDurvalumabAtezolizumabCancerClinical trialSurgeryBladder and Urothelial Cancer TreatmentsCancer, Stress, Anesthesia, and Immune ResponseUrinary Bladder and Prostate Research